Target Name: OOEP
NCBI ID: G441161
Review Report on OOEP Target / Biomarker Content of Review Report on OOEP Target / Biomarker
OOEP
Other Name(s): KH homology domain-containing protein 2 | OEP19 | oocyte and embryo protein 19 | hOEP19 | oocyte expressed protein | oocyte expressed protein homolog (dog) | KHDC2 | OOEP_HUMAN | KH homology domain containing 2 | HOEP19 | oocyte-expressed protein homolog | FLOPED | Oocyte- and embryo-specific protein 19 | Oocyte-expressed protein homolog | Oocyte expressed protein | oocyte- and embryo-specific protein 19 | C6orf156

OOEP (KH Homology Domain-Containing Protein 2) as a Drug Target and Biomarker

Introduction

Overexpression of the protein OOEP (KH Homology Domain-Containing Protein 2) has been identified as a potential therapeutic approach for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure, characterized by a KH domain and a N-terminal transmembrane region, has led to a high degree of structural flexibility and the potential for diverse functions in various cellular processes. Although the exact mechanism of OOEP's function remains elusive, its potential as a drug target or biomarker is of great interest to researchers.

Structure and Function

The KH domain is a conserved region that is found in various proteins, including the transcription factor Nrf2 and the voltage-dependent calcium channel Ca2+-ATPase CaM. This region is known to play a crucial role in the regulation of DNA double- strand break repair, DNA replication, and gene expression. OOEP's KH domain is similar to that of Nrf2 and shares similar secondary structure elements, such as a conserved core and a N-terminal extension.

The N-terminal transmembrane region of OOEP is characterized by an extracellular domain that is involved in protein-protein interactions and modulates the protein's stability and localization to the membrane. This region is known to be involved in several cellular processes, including cell signaling, inflammation , and neurotransmission.

Mutational studies have revealed that the OOEP protein is highly susceptible to protein inhibition, which may limit its function in cellular processes. Therefore, the study of OOEP's function and potential as a drug target or biomarker is of great interest.

Drug Target Potential

The OOEP protein has been identified as a potential drug target due to its unique structure and function. Its KH domain and N-terminal transmembrane region provide multiple potential binding sites for small molecules, peptides, or antibodies. Additionally, the N-terminal transmembrane region can be targeted by small molecules, such as those derived from natural products or synthetic compounds, which may modulate its stability or localization to the membrane.

One of the key challenges in targeting OOEP is its expressed levels, as it is a low-abundance protein. However, recent studies have shown that OOEP can be expressed and purified to a high degree, which may open up new avenues for its identification and characterization as a drug target.

Biomarker Potential

OOEP has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function may make it an attractive candidate for diagnostic or therapeutic applications.

For cancer, OOEP has been shown to be involved in cell signaling and has been used as a therapeutic agent in various studies. Its KH domain has been shown to play a role in the regulation of DNA double-strand break repair, which may make it a useful target for cancer therapy.

In neurodegenerative diseases, OOEP has been shown to be involved in the regulation of protein synthesis and may be a potential therapeutic target for diseases such as Alzheimer's disease and Parkinson's disease.

In autoimmune disorders, OOEP has been shown to be involved in the regulation of immune cell function and may be a potential therapeutic target for diseases such as rheumatoid arthritis and multiple sclerosis.

Conclusion

In conclusion, OOEP (KH Homology Domain-Containing Protein 2) is a protein with unique structure and function that has the potential to be a drug target or biomarker. Its KH domain and N-terminal transmembrane region provide multiple potential binding sites and its N -Terminal transmembrane region can be targeted by small molecules, making it a promising candidate for drug and biomarker development. Further studies are needed to fully understand its function and potential as a drug target or biomarker.

Protein Name: Oocyte Expressed Protein

Functions: As part of the OOEP-KHDC3L scaffold, recruits BLM and TRIM25 to DNA replication forks, thereby promoting the ubiquitination of BLM by TRIM25, enhancing BLM retainment at replication forks and therefore promoting stalled replication fork restart (By similarity). Positively regulates the homologous recombination-mediated DNA double-strand break (DSB) repair pathway by regulating ATM activation and RAD51 recruitment to DSBs in oocytes (By similarity). Thereby contributes to oocyte survival and the resumption and completion of meiosis (By similarity). As a member of the subcortical maternal complex (SCMC), plays an essential role for zygotes to progress beyond the first embryonic cell divisions via regulation of actin dynamics (By similarity). Required for the formation of F-actin cytoplasmic lattices in oocytes which in turn are responsible for symmetric division of zygotes via the regulation of mitotic spindle formation and positioning (By similarity)

The "OOEP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OOEP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OOSP1 | OOSP2 | OPA1 | OPA1-AS1 | OPA3 | OPALIN | OPCML | OPHN1 | Opioid receptor | OPLAH | OPN1LW | OPN1MW | OPN1MW3 | OPN1SW | OPN3 | OPN4 | OPN5 | OPRD1 | OPRK1 | OPRL1 | OPRM1 | OPRPN | OPTC | OPTN | OR10A2 | OR10A3 | OR10A4 | OR10A5 | OR10A6 | OR10A7 | OR10AA1P | OR10AB1P | OR10AC1 | OR10AD1 | OR10AF1P | OR10AG1 | OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1 | OR10Z1 | OR11A1 | OR11G2 | OR11H1 | OR11H12 | OR11H13P | OR11H2 | OR11H5P | OR11H6 | OR11H7 | OR11J2P | OR11J5P | OR11K2P | OR11L1 | OR11M1P | OR12D2 | OR12D3 | OR13A1 | OR13C2 | OR13C3 | OR13C4 | OR13C5 | OR13C8 | OR13C9 | OR13D1 | OR13F1 | OR13G1 | OR13H1 | OR13J1 | OR13Z2P | OR14A16 | OR14A2 | OR14C36 | OR14I1